The Devyser blog

Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announces that it has...

Devyser today announced that it entered a strategic agreement with Illumina, a global leader in DNA...

Devyser is proud to announce that the company has been awarded a tender by Oslo University Hospital...

Devyser, a leading provider of advanced genetic testing solutions, has been awarded a new tender in...

Devyser is proud to announce that One Lambda Devyser Chimerism and Advyser Chimerism have been...

Devyser today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its...

Devyser today announced the enrollment of the first patient in its Devyser Accept cfDNA clinical...

Devyser, a pioneer in advanced genetic testing solutions, is pleased to announce that its...

With the IVDR transition approaching, European clinical laboratories are preparing for changes that...

The supply of anti-D immunoglobulin, a prophylactic cornerstone of maternal care, has come under...

RhD incompatibility remains a critical concern in prenatal care, with the potential to cause...

Devyser today announced the global launch of Devyser Genomic Blood Typing, a next-generation...